Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Drug

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Fineline Cube May 6, 2026
Company Deals

Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes

Fineline Cube Nov 15, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to...

Policy / Regulatory

China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products

Fineline Cube Nov 15, 2023

The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement...

Company Medical Device

Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU

Fineline Cube Nov 15, 2023

China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received...

Company Deals

Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin

Fineline Cube Nov 15, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership...

Company Deals Digital Hospital

Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China

Fineline Cube Nov 15, 2023

Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into...

Company Drug

Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s

Fineline Cube Nov 15, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...

Company

CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments

Fineline Cube Nov 15, 2023

China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...

Company Deals

Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal

Fineline Cube Nov 14, 2023

China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...

Company Deals R&D

Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery

Fineline Cube Nov 14, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Company Deals

Autobio Diagnostics Expands Strategic Partnership with Guorun Medical Supply Chain Services

Fineline Cube Nov 14, 2023

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with Guorun Medical...

Company Digital

BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal

Fineline Cube Nov 14, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...

Company Drug

Bayer Withdraws Aliqopa FDA Filing Following Missed Phase III Endpoint

Fineline Cube Nov 14, 2023

Germany-based pharmaceutical major Bayer (ETR: BAYN) has announced its decision to withdraw the filing for...

Company Deals

Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics

Fineline Cube Nov 14, 2023

Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led...

Company Deals

AnchorDx Medical Partners with DiaCarta for Global Molecular Diagnostics Development

Fineline Cube Nov 14, 2023

AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered...

Company

Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan

Fineline Cube Nov 14, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical...

Company Deals

Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing

Fineline Cube Nov 14, 2023

Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens...

Company Drug

Servier’s Tibsovo Receives FDA Approval for IDH1-Mutated R/R MDS, Expanding Indications

Fineline Cube Nov 14, 2023

France-based pharmaceutical company Servier has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Huadong Medicine’s Arcalyst (Rilonacept) Filing for CAPSs Accepted by China’s NMPA

Fineline Cube Nov 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that the National...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ HR20031 Accepted for Review by China’s NMPA for Type 2 Diabetes

Fineline Cube Nov 14, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading Chinese pharmaceutical company, has announced that the National...

Company Drug

AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment

Fineline Cube Nov 14, 2023

The National Medical Products Administration (NMPA) of China has indicated on its website that it...

Posts pagination

1 … 438 439 440 … 660

Recent updates

  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
  • China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026
  • UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Company

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.